Message from Dr. Alain Beaudet, CIHR President, about ICR’s Transition


At the end of July 2013, Dr. Morag Park, Scientific Director of CIHR's Institute of Cancer (ICR), will conclude her term. Although this transition is still months away, I would like to thank Dr. Park for her outstanding contributions to health research in Canada.

Over the last four years, under Dr. Park's leadership, ICR has addressed significant health priorities related to cancer research, with a strategic emphasis on the role of lifestyle and the environment; personalized medicine; cancer initiation and progression; and survivorship.

In her role as Scientific Director of CIHR-ICR, Dr. Park was a staunch champion of the importance of collaboration and partnerships within the Canadian cancer research community to better align priorities, reduce duplication and leverage strategic funds, and of the value of interdisciplinary and team training for new cancer researchers. With vision and determination, Dr. Park also catalyzed discussions that led to the development and launch of the CIHR Signature Initiative in Personalized Medicine, which promises to transform the delivery of healthcare to patients from a reactive "one-size-fits-all" system towards a system of predictive, preventive, and precision care.

Over the coming year, ICR staff in Montreal and Ottawa, the Institute's Advisory Board, and senior CIHR management in Ottawa will be working to ensure that this transition proceeds as effectively as possible.

Recruitment for a new Scientific Director for ICR will begin shortly. I am confident that the next Scientific Director will continue to provide the necessary vision and leadership to further build support for research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.


Alain Beaudet, M.D., Ph.D.
President, Canadian Institutes of Health Research

Date modified: